MasterCard Inc vs Smith & Nephew plc — how do they compare? MasterCard Inc trades at $559.19 (market cap $491.83B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: MasterCard Inc is far larger — about 39.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| MA | SNN | |
|---|---|---|
Market Cap | $491.83B | $12.54B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $38.70 |
52-Week Low | $471.55 | $28.73 |
Enterprise Value | $504.86B | $15.57B |
Dividend Yield | 0.62% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $563.17, up 0.04% today, with a bullish technical signal and strong institutional buying. The stock shows robust fundamentals, with revenue growing from $22.2B in 2022 to $32.8B in 2025 and net income margins above 45%. Recent earnings beats and a consensus price target of $660.85 reflect optimism, though high valuation ratios like a P/E of 30.98 warrant caution.
Outlook is positive due to consistent earnings growth, expanding digital payment initiatives, and analyst buy ratings. Risks include competitive pressures from new payment technologies and regulatory scrutiny. The stock offers upside potential but requires monitoring of valuation and market shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →